Literature DB >> 19820364

Fatigue and quality of life after risk-reducing salpingo-oophorectomy in women at increased risk for hereditary breast-ovarian cancer.

Trond M Michelsen1, Anne Dørum, Claes G Tropé, Sophie D Fosså, Alv A Dahl.   

Abstract

BACKGROUND: Risk-reducing salpingo-oophorectomy (RRSO) is the safest intervention for prevention of ovarian cancer in women at increased risk for hereditary breast-ovarian cancer. Little is known about other effects of RRSO. The objective of this study was to investigate quality of life (QoL) and fatigue in a sample of women who had RRSO for increased cancer risk and to compare the findings with those of age-matched controls from the general population (NORM).
MATERIALS AND METHODS: In a cross-sectional follow-up mailed questionnaire design, 301 (67%) of 450 invited Norwegian women with RRSO attended. The questionnaire contained measures of QoL, fatigue, anxiety/depression, and body image, and questions about demography, lifestyle, and morbidity. The findings were compared with those of the NORM.
RESULTS: For RRSO women, mean age at survey was 53.7 years (SD, 9.2), mean age at RRSO was 48.4 years (SD 8.4), and median follow-up time was 5.0 years (range, 1-15 years). No clinically significant differences were observed between RRSO and NORM for any of the QoL or fatigue dimensions. In subgroup analyses of the RRSO group, no clinically significant differences in QoL and fatigue were observed between those who had surgery before or after age 50 years, or between BRCA1/2 carriers and women with unknown mutation statuses. Women who had cancer (32%), however, showed clinically significant lower levels of QoL and more fatigue than women without cancer.
CONCLUSIONS: Women who had RRSO showed similar levels of QoL and fatigue as NORM. Women who had cancer before RRSO had lower levels of QoL and more fatigue.

Entities:  

Mesh:

Year:  2009        PMID: 19820364     DOI: 10.1111/IGC.0b013e3181a83cd5

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  Ovarian Cancer Prevention in High-risk Women.

Authors:  Sarah M Temkin; Jennifer Bergstrom; Goli Samimi; Lori Minasian
Journal:  Clin Obstet Gynecol       Date:  2017-12       Impact factor: 2.190

2.  Factors associated with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for breast and ovarian cancer.

Authors:  Cyril Touboul; Catherine Uzan; Jean Laurent Ichanté; Olivier Caron; Ariane Dunant; Sarah Dauchy; Sébastien Gouy; Brigitte Bressac de Paillerets; Philippe Morice; Suzette Delaloge
Journal:  Oncologist       Date:  2011-07-17

Review 3.  New strategies in ovarian cancer: uptake and experience of women at high risk of ovarian cancer who are considering risk-reducing salpingo-oophorectomy.

Authors:  Suzanne M Miller; Pagona Roussi; Mary B Daly; John Scarpato
Journal:  Clin Cancer Res       Date:  2010-09-09       Impact factor: 12.531

Review 4.  Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond.

Authors:  M J Hall; E I Obeid; S C Schwartz; G Mantia-Smaldone; A D Forman; M B Daly
Journal:  Gynecol Oncol       Date:  2016-01-23       Impact factor: 5.482

5.  Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.

Authors:  Phuong L Mai; Helen Q Huang; Lari B Wenzel; Paul K Han; Richard P Moser; Gustavo C Rodriguez; John Boggess; Thomas J Rutherford; David E Cohn; Noah D Kauff; Kelly-Anne Phillips; Kelly Wilkinson; Robert M Wenham; Chad Hamilton; Matthew A Powell; Joan L Walker; Mark H Greene; Martee L Hensley
Journal:  Gynecol Oncol       Date:  2019-11-21       Impact factor: 5.482

6.  Pathologic findings at risk-reducing salpingo-oophorectomy (RRSO) in germline BRCA mutation carriers with breast cancer: significance of bilateral RRSO at the optimal age in germline BRCA mutation carriers.

Authors:  Young Jae Lee; Shin Wha Lee; Kyu Rae Kim; Kyung Hae Jung; Jong Won Lee; Yong Man Kim
Journal:  J Gynecol Oncol       Date:  2016-08-08       Impact factor: 4.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.